Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000928011
Ethics application status
Approved
Date submitted
26/10/2010
Date registered
2/11/2010
Date last updated
2/11/2010
Type of registration
Retrospectively registered
Titles & IDs
Public title
A proprietary blend of Phellodendron and Crape Myrtle improves glucose tolerance in response to an oral dextrose load in exercise-trained non-diabetic men
Query!
Scientific title
A proprietary blend of Phellodendron and Crape Myrtle improves glucose tolerance in response to an oral dextrose load in exercise-trained non-diabetic men
Query!
Secondary ID [1]
252884
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
glucose tolerance
258416
0
Query!
Condition category
Condition code
Metabolic and Endocrine
258583
258583
0
0
Query!
Normal metabolism and endocrine development and function
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
1) Oral capsule was the mode of administration
a)proprietary blend of 750mg of Phellodendron [bark] and Crape Myrtle [Lagerstroemia Speciosia] stem [Anabolic Pump (TM); USPlabs, LLC, Dallas, TX]
b)single dose only
7 day washout period
Query!
Intervention code [1]
257411
0
Treatment: Drugs
Query!
Comparator / control treatment
single oral dose of microcrystalline cellulose
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
259426
0
serum glucose
Query!
Assessment method [1]
259426
0
Query!
Timepoint [1]
259426
0
The OGTT was administered 15 minutes after the capsule.
pre - capsule
15min, 30min, 45min, 60min, and 75min post - oral glucose tolerance test
Query!
Secondary outcome [1]
265975
0
serum insulin
Query!
Assessment method [1]
265975
0
Query!
Timepoint [1]
265975
0
The OGTT was administered 15 minutes after the capsule.
pre - capsule
15min, 30min, 45min, 60min, and 75min post - oral glucose tolerance test
Query!
Eligibility
Key inclusion criteria
Ten healthy, exercise-trained men.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
35
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Subjects were not smokers, and did not have diagnosed cardiovascular or metabolic disease (including diabetes). Subjects were not using dietary supplements believed to influence blood glucose disposal.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
a randomized, double-blind, cross-over design
Allocation concealled by numbered containers and central randomisation by computer
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation by using a randomization table created by a computer software
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
15/07/2010
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
2975
0
United States of America
Query!
State/province [1]
2975
0
Tennessee
Query!
Funding & Sponsors
Funding source category [1]
257852
0
Commercial sector/Industry
Query!
Name [1]
257852
0
USPlabs, LLC
Query!
Address [1]
257852
0
2221 Manana Drive STE 120
Dallas, TX 75220
Query!
Country [1]
257852
0
United States of America
Query!
Primary sponsor type
University
Query!
Name
The University of Memphis
Query!
Address
The University of Memphis
161F Elma Neal Roane Fieldhouse
Memphis, TN 38152
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
257161
0
Individual
Query!
Name [1]
257161
0
Dr. Richard J Bloomer
Query!
Address [1]
257161
0
The University of Memphis
161F Elma Neal Roane Fieldhouse
Memphis, TN 38152
Query!
Country [1]
257161
0
United States of America
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
259887
0
University of Memphis Institutional Review Board
Query!
Ethics committee address [1]
259887
0
University of Memphis Memphis, TN 38152
Query!
Ethics committee country [1]
259887
0
United States of America
Query!
Date submitted for ethics approval [1]
259887
0
Query!
Approval date [1]
259887
0
Query!
Ethics approval number [1]
259887
0
Query!
Summary
Brief summary
Recently, a finished product containing a proprietary blend of Phellodendron and Crape Myrtle has been developed. It is believed that this product may aid in the management of blood glucose and allow for increased glucose clearance following an oral glucose tolerance test (OGTT). Such effects may be associated with a reduction in adverse outcomes associated with poor blood glucose management, as well as enhanced glucose uptake into skeletal muscle (to be stored as glycogen—an objective of many athletes). In relation to the latter effect, this particular product is purported to act as a nutrient partitioning agent, working to theoretically improve body composition by preferentially shuttling glucose into skeletal muscle as opposed to adipose tissue. The present study sought to investigate the acute effects of this nutritional supplement on serum glucose and insulin in response to an OGTT.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
31783
0
Query!
Address
31783
0
Query!
Country
31783
0
Query!
Phone
31783
0
Query!
Fax
31783
0
Query!
Email
31783
0
Query!
Contact person for public queries
Name
15030
0
Robert Canale
Query!
Address
15030
0
The University of Memphis
161C Elma Neal Roane Fieldhouse
Memphis, TN 38152
Query!
Country
15030
0
United States of America
Query!
Phone
15030
0
+1 901-678-1547
Query!
Fax
15030
0
Query!
Email
15030
0
[email protected]
Query!
Contact person for scientific queries
Name
5958
0
Dr. Richard Bloomer
Query!
Address
5958
0
Richard J. Bloomer, PhD, CSCS
The University of Memphis
161F Elma Neal Roane Fieldhouse
Memphis, TN 38152
Query!
Country
5958
0
United States of America
Query!
Phone
5958
0
+1 901-678-4341
Query!
Fax
5958
0
Query!
Email
5958
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF